-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Neutral on Recursion Pharmaceuticals, Lowers Price Target to $6

Benzinga·02/26/2026 11:55:50
Listen to the news
B of A Securities analyst Michael Ryskin maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Neutral and lowers the price target from $7 to $6.